Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 487 entries
Sorted by: Best Match Show Resources per page
FDA rejects first-in-class osteoporosis drug.

Nature reviews. Drug discovery

Mullard A.
PMID: 28860584
Nat Rev Drug Discov. 2017 Sep 01;16(9):593. doi: 10.1038/nrd.2017.176.

No abstract available.

Cite
Mullard A. FDA rejects first-in-class osteoporosis drug. Nat Rev Drug Discov. 2017;16(9):593doi: 10.1038/nrd.2017.176.
Mullard, A. (2017). FDA rejects first-in-class osteoporosis drug. Nature reviews. Drug discovery, 16(9), 593. https://doi.org/10.1038/nrd.2017.176
Mullard, Asher. "FDA rejects first-in-class osteoporosis drug." Nature reviews. Drug discovery vol. 16,9 (2017): 593. doi: https://doi.org/10.1038/nrd.2017.176
Mullard A. FDA rejects first-in-class osteoporosis drug. Nat Rev Drug Discov. 2017 Sep 01;16(9):593. doi: 10.1038/nrd.2017.176. PMID: 28860584.
Copy Download .nbib Format: NLM
Diabetes drug shows promise in Parkinson disease.

Nature reviews. Drug discovery

Mullard A.
PMID: 28860589
Nat Rev Drug Discov. 2017 Sep 01;16(9):593. doi: 10.1038/nrd.2017.175.

No abstract available.

Cite
Mullard A. Diabetes drug shows promise in Parkinson disease. Nat Rev Drug Discov. 2017;16(9):593doi: 10.1038/nrd.2017.175.
Mullard, A. (2017). Diabetes drug shows promise in Parkinson disease. Nature reviews. Drug discovery, 16(9), 593. https://doi.org/10.1038/nrd.2017.175
Mullard, Asher. "Diabetes drug shows promise in Parkinson disease." Nature reviews. Drug discovery vol. 16,9 (2017): 593. doi: https://doi.org/10.1038/nrd.2017.175
Mullard A. Diabetes drug shows promise in Parkinson disease. Nat Rev Drug Discov. 2017 Sep 01;16(9):593. doi: 10.1038/nrd.2017.175. PMID: 28860589.
Copy Download .nbib Format: NLM
Clinical predictors for sessile serrated polyposis syndrome: A case control study.

World journal of gastrointestinal endoscopy

Wu Y, Mullin A, Stoita A.
PMID: 28979711
World J Gastrointest Endosc. 2017 Sep 16;9(9):464-470. doi: 10.4253/wjge.v9.i9.464.

AIM: To compared individuals with serrated polyposis syndrome (SPS) to those with sessile serrated adenoma (SSA) and adenomas in the setting of endoscopists with high adenoma detection rates at a secondary and tertiary academic centre.METHODS: Retrospectively we collated the...

Cite
Wu Y, Mullin A, Stoita A. Clinical predictors for sessile serrated polyposis syndrome: A case control study. World J Gastrointest Endosc. 2017;9(9):464-470doi: 10.4253/wjge.v9.i9.464.
Wu, Y., Mullin, A., & Stoita, A. (2017). Clinical predictors for sessile serrated polyposis syndrome: A case control study. World journal of gastrointestinal endoscopy, 9(9), 464-470. https://doi.org/10.4253/wjge.v9.i9.464
Wu, Yang, et al. "Clinical predictors for sessile serrated polyposis syndrome: A case control study." World journal of gastrointestinal endoscopy vol. 9,9 (2017): 464-470. doi: https://doi.org/10.4253/wjge.v9.i9.464
Wu Y, Mullin A, Stoita A. Clinical predictors for sessile serrated polyposis syndrome: A case control study. World J Gastrointest Endosc. 2017 Sep 16;9(9):464-470. doi: 10.4253/wjge.v9.i9.464. PMID: 28979711; PMCID: PMC5605346.
Copy Download .nbib Format: NLM
Diabetic foot exams and PQRS.

Family practice management

Mullins A.
PMID: 26977994
Fam Pract Manag. 2016 Mar-Apr;23(2):34.

No abstract available.

Cite
Mullins A. Diabetic foot exams and PQRS. Fam Pract Manag. 2016;23(2):34
Mullins, A. (2016). Diabetic foot exams and PQRS. Family practice management, 23(2), 34.
Mullins, Amy. "Diabetic foot exams and PQRS." Family practice management vol. 23,2 (2016): 34.
Mullins A. Diabetic foot exams and PQRS. Fam Pract Manag. 2016 Mar-Apr;23(2):34. PMID: 26977994.
Copy Download .nbib Format: NLM
TransCelerate makes progress.

Nature reviews. Drug discovery

Mullard A.
PMID: 28356586
Nat Rev Drug Discov. 2017 Mar 30;16(4):229. doi: 10.1038/nrd.2017.63.

No abstract available.

Cite
Mullard A. TransCelerate makes progress. Nat Rev Drug Discov. 2017;16(4):229doi: 10.1038/nrd.2017.63.
Mullard, A. (2017). TransCelerate makes progress. Nature reviews. Drug discovery, 16(4), 229. https://doi.org/10.1038/nrd.2017.63
Mullard, Asher. "TransCelerate makes progress." Nature reviews. Drug discovery vol. 16,4 (2017): 229. doi: https://doi.org/10.1038/nrd.2017.63
Mullard A. TransCelerate makes progress. Nat Rev Drug Discov. 2017 Mar 30;16(4):229. doi: 10.1038/nrd.2017.63. PMID: 28356586.
Copy Download .nbib Format: NLM
General Practitioners at the Deep End: The experience and views of general practitioners working in the most severely deprived areas of Scotland.

Occasional paper (Royal College of General Practitioners)

Watt G, Brown G, Budd J, Cawston P, Craig M, Jamieson R, Langridge S, Lyon A, Mercer S, Morton C, Mullin A, O'Neil J, Paterson E, Sambale P, Watt G, Williamson A.
PMID: 27074888
Occas Pap R Coll Gen Pract. 2012 Apr;(89):i-40.

No abstract available.

Cite
Watt G, Brown G, Budd J, et al. General Practitioners at the Deep End: The experience and views of general practitioners working in the most severely deprived areas of Scotland. Occas Pap R Coll Gen Pract. 2012;(89):i-40
Watt, G., Brown, G., Budd, J., Cawston, P., Craig, M., Jamieson, R., Langridge, S., Lyon, A., Mercer, S., Morton, C., Mullin, A., O'Neil, J., Paterson, E., Sambale, P., Watt, G., & Williamson, A. (2012). General Practitioners at the Deep End: The experience and views of general practitioners working in the most severely deprived areas of Scotland. Occasional paper (Royal College of General Practitioners), (89), i-40.
Watt, Graham, et al. "General Practitioners at the Deep End: The experience and views of general practitioners working in the most severely deprived areas of Scotland." Occasional paper (Royal College of General Practitioners) vol. ,89 (2012): i-40.
Watt G, Brown G, Budd J, Cawston P, Craig M, Jamieson R, Langridge S, Lyon A, Mercer S, Morton C, Mullin A, O'Neil J, Paterson E, Sambale P, Watt G, Williamson A. General Practitioners at the Deep End: The experience and views of general practitioners working in the most severely deprived areas of Scotland. Occas Pap R Coll Gen Pract. 2012 Apr;(89):i-40. PMID: 27074888; PMCID: PMC3627459.
Copy Download .nbib Format: NLM
Thyroid Hormone-Regulated Cardiac microRNAs are Predicted to Suppress Pathological Hypertrophic Signaling.

Frontiers in endocrinology

Janssen R, Zuidwijk MJ, Kuster DW, Muller A, Simonides WS.
PMID: 25368602
Front Endocrinol (Lausanne). 2014 Oct 20;5:171. doi: 10.3389/fendo.2014.00171. eCollection 2014.

Cardiomyocyte size in the healthy heart is in part determined by the level of circulating thyroid hormone (TH). Higher levels of TH induce ventricular hypertrophy, primarily in response to an increase in hemodynamic load. Normal cardiac function is maintained...

Cite
Janssen R, Zuidwijk MJ, Kuster DW, et al. Thyroid Hormone-Regulated Cardiac microRNAs are Predicted to Suppress Pathological Hypertrophic Signaling. Front Endocrinol (Lausanne). 2014;5:171doi: 10.3389/fendo.2014.00171.
Janssen, R., Zuidwijk, M. J., Kuster, D. W., Muller, A., & Simonides, W. S. (2014). Thyroid Hormone-Regulated Cardiac microRNAs are Predicted to Suppress Pathological Hypertrophic Signaling. Frontiers in endocrinology, 5171. https://doi.org/10.3389/fendo.2014.00171
Janssen, Rob, et al. "Thyroid Hormone-Regulated Cardiac microRNAs are Predicted to Suppress Pathological Hypertrophic Signaling." Frontiers in endocrinology vol. 5 (2014): 171. doi: https://doi.org/10.3389/fendo.2014.00171
Janssen R, Zuidwijk MJ, Kuster DW, Muller A, Simonides WS. Thyroid Hormone-Regulated Cardiac microRNAs are Predicted to Suppress Pathological Hypertrophic Signaling. Front Endocrinol (Lausanne). 2014 Oct 20;5:171. doi: 10.3389/fendo.2014.00171. eCollection 2014. PMID: 25368602; PMCID: PMC4202793.
Copy Download .nbib Format: NLM
Heart Rate Unreliability during Interval Training Recovery in Middle Distance Runners.

Journal of sports science & medicine

Tocco F, Sanna I, Mulliri G, Magnani S, Todde F, Mura R, Ghiani G, Concu A, Melis F, Crisafulli A.
PMID: 25983598
J Sports Sci Med. 2015 May 08;14(2):466-72. eCollection 2015 Jun.

Heart rate (HR) was tested as a reliable index for recovery management during interval training (IT), considering its relationship with the several factors involved in respiratory, metabolic and cardiovascular homeostasis. Thirteen runners underwent two different IT sessions: at 80%...

Cite
Tocco F, Sanna I, Mulliri G, et al. Heart Rate Unreliability during Interval Training Recovery in Middle Distance Runners. J Sports Sci Med. 2015;14(2):466-72
Tocco, F., Sanna, I., Mulliri, G., Magnani, S., Todde, F., Mura, R., Ghiani, G., Concu, A., Melis, F., & Crisafulli, A. (2015). Heart Rate Unreliability during Interval Training Recovery in Middle Distance Runners. Journal of sports science & medicine, 14(2), 466-72.
Tocco, Filippo, et al. "Heart Rate Unreliability during Interval Training Recovery in Middle Distance Runners." Journal of sports science & medicine vol. 14,2 (2015): 466-72.
Tocco F, Sanna I, Mulliri G, Magnani S, Todde F, Mura R, Ghiani G, Concu A, Melis F, Crisafulli A. Heart Rate Unreliability during Interval Training Recovery in Middle Distance Runners. J Sports Sci Med. 2015 May 08;14(2):466-72. eCollection 2015 Jun. PMID: 25983598; PMCID: PMC4424478.
Copy Download .nbib Format: NLM
Esophagopericardial fistula: an unexpected dreaded complication of treatment of leak following revisional sleeve gastrectomy by endoscopic internal drainage.

Journal of surgical case reports

Meunier H, Menahem B, Mulliri A, Fohlen A, Contival N, Le Roux Y, Desgue J, Lubrano J, Alves A.
PMID: 28458855
J Surg Case Rep. 2017 Mar 07;2017(3):rjx049. doi: 10.1093/jscr/rjx049. eCollection 2017 Mar.

Esophagopericardial fistula (EPF) is an uncommon but life-threatening complication of upper gastrointestinal tract surgery or endoscopy, which is related to anastomotic breakdown, chronic infection or esophageal traumatism. We first describe the first case of an EPF secondary to double...

Cite
Meunier H, Menahem B, Mulliri A, et al. Esophagopericardial fistula: an unexpected dreaded complication of treatment of leak following revisional sleeve gastrectomy by endoscopic internal drainage. J Surg Case Rep. 2017;2017(3):rjx049doi: 10.1093/jscr/rjx049.
Meunier, H., Menahem, B., Mulliri, A., Fohlen, A., Contival, N., Le Roux, Y., Desgue, J., Lubrano, J., & Alves, A. (2017). Esophagopericardial fistula: an unexpected dreaded complication of treatment of leak following revisional sleeve gastrectomy by endoscopic internal drainage. Journal of surgical case reports, 2017(3), rjx049. https://doi.org/10.1093/jscr/rjx049
Meunier, Hugo, et al. "Esophagopericardial fistula: an unexpected dreaded complication of treatment of leak following revisional sleeve gastrectomy by endoscopic internal drainage." Journal of surgical case reports vol. 2017,3 (2017): rjx049. doi: https://doi.org/10.1093/jscr/rjx049
Meunier H, Menahem B, Mulliri A, Fohlen A, Contival N, Le Roux Y, Desgue J, Lubrano J, Alves A. Esophagopericardial fistula: an unexpected dreaded complication of treatment of leak following revisional sleeve gastrectomy by endoscopic internal drainage. J Surg Case Rep. 2017 Mar 07;2017(3):rjx049. doi: 10.1093/jscr/rjx049. eCollection 2017 Mar. PMID: 28458855; PMCID: PMC5400488.
Copy Download .nbib Format: NLM
Plasmon-enhanced waveguide for dispersion compensation in mid-infrared quantum cascade laser frequency combs.

Optics letters

Bidaux Y, Sergachev I, Wuester W, Maulini R, Gresch T, Bismuto A, Blaser S, Muller A, Faist J.
PMID: 28409809
Opt Lett. 2017 Apr 15;42(8):1604-1607. doi: 10.1364/OL.42.001604.

We demonstrate dispersion compensation in mid-infrared quantum cascade laser frequency combs (FCs) emitting at 7.8 μm using the coupling of a dielectric waveguide to a plasmonic resonance in the top cladding layer of the latter. Devices with group velocity...

Cite
Bidaux Y, Sergachev I, Wuester W, et al. Plasmon-enhanced waveguide for dispersion compensation in mid-infrared quantum cascade laser frequency combs. Opt Lett. 2017;42(8):1604-1607doi: 10.1364/OL.42.001604.
Bidaux, Y., Sergachev, I., Wuester, W., Maulini, R., Gresch, T., Bismuto, A., Blaser, S., Muller, A., & Faist, J. (2017). Plasmon-enhanced waveguide for dispersion compensation in mid-infrared quantum cascade laser frequency combs. Optics letters, 42(8), 1604-1607. https://doi.org/10.1364/OL.42.001604
Bidaux, Yves, et al. "Plasmon-enhanced waveguide for dispersion compensation in mid-infrared quantum cascade laser frequency combs." Optics letters vol. 42,8 (2017): 1604-1607. doi: https://doi.org/10.1364/OL.42.001604
Bidaux Y, Sergachev I, Wuester W, Maulini R, Gresch T, Bismuto A, Blaser S, Muller A, Faist J. Plasmon-enhanced waveguide for dispersion compensation in mid-infrared quantum cascade laser frequency combs. Opt Lett. 2017 Apr 15;42(8):1604-1607. doi: 10.1364/OL.42.001604. PMID: 28409809.
Copy Download .nbib Format: NLM
Reining in the supersized Phase I cancer trial.

Nature reviews. Drug discovery

Mullard A.
PMID: 27380469
Nat Rev Drug Discov. 2016 Jul;15(7):516. doi: 10.1038/nrd.2016.129. Epub 2016 Jun 17.

No abstract available.

Cite
Mullard A. Reining in the supersized Phase I cancer trial. Nat Rev Drug Discov. 2016;15(7):516doi: 10.1038/nrd.2016.129.
Mullard, A. (2016). Reining in the supersized Phase I cancer trial. Nature reviews. Drug discovery, 15(7), 516. https://doi.org/10.1038/nrd.2016.129
Mullard, Asher. "Reining in the supersized Phase I cancer trial." Nature reviews. Drug discovery vol. 15,7 (2016): 516. doi: https://doi.org/10.1038/nrd.2016.129
Mullard A. Reining in the supersized Phase I cancer trial. Nat Rev Drug Discov. 2016 Jul;15(7):516. doi: 10.1038/nrd.2016.129. Epub 2016 Jun 17. PMID: 27380469.
Copy Download .nbib Format: NLM
What does Pfizer's merger mean for drug development?.

Lancet (London, England)

Mullard A.
PMID: 26766335
Lancet. 2016 Jan 02;387(10013):14-5. doi: 10.1016/S0140-6736(15)01351-3.

No abstract available.

Cite
Mullard A. What does Pfizer's merger mean for drug development?. Lancet. 2016;387(10013):14-5doi: 10.1016/S0140-6736(15)01351-3.
Mullard, A. (2016). What does Pfizer's merger mean for drug development?. Lancet (London, England), 387(10013), 14-5. https://doi.org/10.1016/S0140-6736(15)01351-3
Mullard, Asher. "What does Pfizer's merger mean for drug development?." Lancet (London, England) vol. 387,10013 (2016): 14-5. doi: https://doi.org/10.1016/S0140-6736(15)01351-3
Mullard A. What does Pfizer's merger mean for drug development?. Lancet. 2016 Jan 02;387(10013):14-5. doi: 10.1016/S0140-6736(15)01351-3. PMID: 26766335.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 487 entries